医療関係者様






当院では、国内における医療体系確立の貢献に対して
支援を積極的に行なっております。
その一環として、「医師主導型臨床試験」ならびに「開発治験」などをIRBを経て参画させて頂いております。

当院に試験参加要請のご依頼がございましたらお気軽に下記までお問い合わせ下さい。

尚、当院は外部IRBに委託し、院内倫理の整備を行なっております。


【当院で現在参画している試験】

大規模臨床試験(参加分)
1)JELIS
 Effects of eicosapentaenoic acid on major coronary events in hyperchoresterolaemic patients(JELIS),a randomized open-label,blinded endpoint analisis.Lancet 369,1090-1998:2007 AHA late breaking:2006Investigator

2)CASE-J
Effects of candesartan compared with amlodipine in hypertensive patients with high cardiovascular risks.Candesartan antihypertensive survival evaluation in japan trial. Hypertension:51,393-398:2008ISH:2006Investigator

3)JATOS
The Japanese trial to assess optimal systolic blood pressure in elderly hypertensive patientsHypertension Research 28,513-520,2005

Principal result of the Japanese trial to assess optimal systolic blood pressurein elderly hypertensive patients (JATOS) Hypertension Research 31,2115-2127,2008ISH:2006JATOS study Organization Study Promoting Communitee, Investigator

4)COPE
ISH:2008Investgator

5)ARB,ACEI BrainMRI(奈良医大)
Investigator

6)J-PAD(熊本大、奈良医大)
Low-dose aspirin for primary prevention of atherosclerotic events in patients with type 2 diabetes : a randomized control trial.JAMA:300:2134-2141:2008 IF 31.4
AHA late breaking:2008Investigator

7)COLM(大阪大)
ISH:2008 Investigator
8)NIPPON Investigator(京都大学)
9)EDEN Investigator (岡山大)ESH 2011
10)J-HOP Investigator(自治医大)
11)LEM Investigator 第41回日本動脈硬化学会、2009
12)JAMP Investigator(自治医大)
13)2次性高血圧研究 Investigator(京都大学)
14)ABC-J Investigator (自治医大)
15)EDEN2 Investigator (岡山大学)
16)REAL-CAD Investigator (東京大学)
17)PROGRESS Investigator (
熊本大学
)


【国際学会学会発表】
1)Takeshi Takami, Tsuneyuki Suzuki and Kozo Okamoto
Changes in TSH and 11-deoxycorticosterone (DOC) in hypertension.
6th International .Symposium. on SHR and Related Studies. 1989, Iowa, USA
2) Takeshi Takami
Effect of antihypertensive agents on platelet function in patients with essential hypertension.
4th International Symposium. Cardiovascular .Pharmacotherapy(ISCP). 1991, Geneva, Switzerland3)Takeshi Takami
Heart and renal failure induced by steroid(from circulation aspect)
26th International .Congress of Internal Medicine. 2002, kyoto,Japan
4) JATOS study group (Masao Ishii , Takeshi Takami et al)
Large Clinical Trial JATOS
21th Scientific meeting of international society of hypertension (ISH) 2006, Fukuoka
5)Takeshi Takami
Effect of high dose valsartan on arterial stiffness in masked hypertension compared with valsaltan plus diuretic22nd ISH , 2008, Berlin, Germany
6) Takeshi Takami
Effect of high dose valsartan on arterial stiffness in masked hypertension compared with valsaltan plus diuretic 18th ESH, 2008, Berlin, Germany


【英文原著(代表的なもの)】

1)Toshiyuki Hamaoka, Uki Yamashita, Takeshi Takami and Masayasu Kitagawa
The mechanism of tolerance induction in thymus-derived lymphocytes.
The Journal of Experimental Medicine, 141, 1308-1328, 1975

2)Uki Yamashita, Takeshi Takami and Masayasu Kitagawa
Induction of anti-hapten antibody responce by hapten-isologous carrier conjugate.
Cellular Immunology, 18, 369-410, 1975

3)Uki Yamashita, Toshiyuki Hamaoka, Takeshi Takami and Masayasu Kitagawa
Immune maturation of T lymphocye:Seqential changes in the functional specificity and apperentaffinity of hapten-reactive helper T cells during an immune response.Cellular Immunology,22, 152-164,1976

4)Uki Yamashita, ,Takeshi Takami, Toshiyuki Hamaoka and Masayasu Kitagawa
The role of hapten-reactive T lymphocytes in the induction of autoimmunity in mice T
Cellular Immunology, 25,15-31,1976

5)Uki Yamashita, Takeshi Takami, Toshiyuki Hamaoka and Masayasu Kitagawa
The role of hapten-reactive T lymphocytes in the induction of autoimmunity in miceU
Cellular Immunology,25, 32-40,1976

6)Takeshi Takami, Hiroyuki Ito,Tsuneyuki Suzuki and Kozo Okamoto
Changes in TSH and 11-deoxycorticosterone(DOC) in hypertension.Clin. and Exper.
Hyper., A13,991-998,1991

7)Takeshi Takami ,Hiroyuki Ito and Tsuneyuki Suzuki
Decreased norepinephrine content in the medulla oblongata in severely hypertensive rats.
Clin. . Exper. Pharmacol. Physiol. 20, 161-167, 1993

8)Takeshi Takami, Minori Shigematu
Effects of calcium channel antagonists on left ventricular hypertrophy and diastolic function in patients with essential hypertension.Clinical and Experimental Hypertension,25(8),525-535,2003

9)Takeshi Takami, Minori Shigematsu
Efficacy of various antihypertensive agents as evaluted by indices of vascularstiffness in elderly hypertensive patients.Hypertension Research,26(8), 609-614,2003

10)JATOS study group (Takeshi Takami et al)
The Japanese trial to assess optimal systolic blood pressure in elderly hypertensive patientsHypertension Reseach 28,513-520,2005

11)JATOS study group(Takeshi Takami et al)
Principal result of the Japanese trial to assess optimal systolic blood pressurein elderly hypertensive patients (JATOS)Hypertension Research 31,2115-2127,2008 

12)Takeshi Takami
Evaluation of arterial stiffness in morning hypertension under high dose valsartan
compared to valsartan plus low dose diuretic
Hypertension Research 32:1086-1090: 2009

13)Takeshi Takami, Yoshihiko Saito
Differential Effects of Azelnidipine with OlmesaRTAn and Amlodipine with Olmesartan on Central Blood Pressure and LVMI in Hypertensive Patients (AORTA study).
Vascular Health and Risk Management. 7:383-390:2011.


14)Takeshi Takami,Yoshihiko Saito
Effects of smoking cessation on central bloood pressure and arterial stiffness.
Vascular Health and Risk Management.7:633-638:2011.

15)Takeshi Takami, Shigeru Yamano, Sadanori Okada, Mio Sakuma, Takeshi Morimoto, Hiroshi Hashimoto, Satoshi Somekawa, Yoshihiko Saito
Major risk factors for the appearance of white matter lesions on MRI in hypertensive patients with controlled blood pressure.
Vascular Health and Risk Management. 8:169-176:2012.

16)Takeshi Takami, Hiroshi Ito, Katsuhisa Ishii, Kenei Shimada, Katsunori Iwakura, Hiroyuki Watanabe, Shota Fukuda, Junichi Yoshikawa
Adding thiazide to a renin-angiotensin blocker regimen to improve left ventricular relaxation in diabetes and non-diabetes patients with hypertension.
Drug Design, Development and Therapy. 6:225-233: 2012

17) Takeshi Takam,Yoshihiko Saito
Azelnidipine plus Olmesartan vs Amlodipine plus Olmesartan on Arterial Stiffness and Cardiac Function in Hypertensive Patients: A randomized trial
Drug Design, Development and Therapy 7:175-183:2013

18) Yamano S, Horii1 M,
Takami T, Sakuma M, Morimoto T, Okada S, Taoka T, Kichikawa K, Sasamura H, Itoh H, Furuya Y, Ueno S, Imamura T, Sugiyama S, Ogawa H, Saito Y.
Comparison between angiotensin converting enzyme inhibitors and angiotensin receptor blockers on the risk of stroke recurrence and longitudinal progression of white matter lesions and silent brain infarcts on MRI (CEREBRAL study): Rationale, design, and methodology.
Int J Stroke, 2013(in press)


                国際論文査読

1) Journal of Hypertension Suppl. 2008
2) Vascular Health and Risk Management 2010.
3) Integrated Blood Pressure Control 2010.
4) Vascular Health and Risk Management 2011.
5) Journal of Human Hypertension 2011.
6) Vascular Health and Risk Management 2012.
7) Therapeutics and Clinical Risk Management 2012.
8) Hypertension Research 2012.
9) Vascular Health and Risk Management 2012.
10) Therapeutics and Clinical Risk Management 2012.
11) Therapeutics and Clinical Risk Management 2012.
12) Cardiovascular Diabetology 2012.
13) The Most Sinai Journal of Medicine (MSJM) 2012.
14) Vascular Health and Risk Management 2012.
15) Vascular Health and Risk Management 2012

16) Patient Preference and Adherence 2012
17) Neurological Research 2012
18) Patient Preference and Adherence 2012
19) Integrated Blood Pressure Control 2013
20)Integrated Blood Pressure Control 2013
21) Vascular Health and Risk Management 2013
22)Integrated Blood Pressure Control 2013
23)Therapeutics and Clinical Risk Management 2013
24)Integrated Blood Pressure Control 2013
25)Vascular Health and Risk Management 2013

26) Journal Drugs in R&D.2013
27) Cardiovascular Disease iConcept Press Ltd 2013
28)Vascular Health and Risk Management 2013

29)Drug Design, Development and Therapy 2013
30)Vascular Health and Risk Management 2013
31)Therapeutics and Clinical Risk Management 2013
32)Vascular Health and Risk Management 2013

33)Integrated Blood Pressure Control 2014
34)Circulation Research 2014
35)Clinical Interventions in Aging 2014